Milk and dairy foods: implications for cardiometabolic health
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - August 12, 2018 Category: Cardiology Tags: Editorial Source Type: research
Leveling-off of declining trend of cardiovascular disease-related mortality in the USA: the challenge to rein in obesity and diabetes epidemic
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Viewpoint Source Type: research
Glycemic variability is associated with myocardial damage in nondiabetic patients with ST-elevation myocardial infarction
Background
Glycemic variability (GV) induces coronary microcirculatory disturbance and myocardial damage in diabetic patients with acute myocardial infarction. However, in nondiabetic acute myocardial infarction patients, the relationship between GV and myocardial damage remains unclear.
Patients and methods
We investigated GV with a continuous glucose monitoring system in nondiabetic ST-segment elevation myocardial infarction patients treated with emergent percutaneous coronary intervention. GV was expressed as the mean amplitude of glycemic excursions (MAGE). Myocardial damage was estimated by myocardial blush grade...
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Original articles Source Type: research
The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia
Conclusion
Plasma endocan levels may reflect the presence of isolated CAE, suggesting that endocan may be involved in the pathogenesis of isolated CAE. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Original articles Source Type: research
Advances in the relationship between Kruppel-like factor 15 and cardiovascular disease research
Kruppel-like factor 15 (KLF15) is a subtype of the Kruppel-like family of transcription factors (KLFs). KLFs have three high-fidelity zinc fingers at the carboxyl terminus that enable them to regulate the biological processes of proliferation, differentiation, cellular development, and apoptosis. KLF15 is highly expressed in the kidney, pancreas, and cardiac and skeletal muscle, and plays an essential role in the development and occurrence of multiple system diseases. In this paper, we underscored the important relationship between KLF15 and cardiovascular diseases such as atherosclerosis, heart failure, arrhythmia, aortic...
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Review article Source Type: research
Diagnostic challenges in supraventricular tachycardia: anticipating value of natriuretic peptides
It is important not to overlook supraventricular tachycardia (SVT) in patients complaining of palpitation or tachycardia-related symptoms but with normal ECG and heart rate in emergency department or outpatient clinics. The severity and presentation of symptoms is highly variable and depends on features including heart rate, duration of tachycardia, underlying heart disease, and individual patient perception. Early measurement of natriuretic peptides in patients presenting with palpitation and/or tachycardia-related symptoms would guide the clinician to rule out tachycardia and/or SVT. High levels of natriuretic peptides w...
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Short report Source Type: research
The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease
Cardiovascular (CV) disease is the leading cause of mortality in patients with type 2 diabetes mellitus. A major factor in the pathogenesis of CV disease is vascular calcification (VC), which is accelerated in type 2 diabetes mellitus. Calcification of the vessel wall contributes to vascular stiffness and left ventricular hypertrophy whereas intimal calcification may predispose to plaque rupture and CV death. The pathogenesis of VC is complex but appears to be regulated by the osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL) signaling pathway, which is involved in bone remodeling. Within the bo...
Source: Cardiovascular Endocrinology - May 10, 2018 Category: Cardiology Tags: Review article Source Type: research
Integrating cardioprotective glucose-lowering medications into clinical practice
Patients with type 2 diabetes suffer from both microvascular and macrovascular complications. Optimal glycemic control is well known to reduce the microvascular complications of retinopathy, nephropathy, and neuropathy. However, despite having multiple classes of antidiabetes medications, we have not been able to favorably affect the cardiovascular (CV) complications of diabetes, which cause considerable morbidity and premature CV mortality in patients with diabetes. The recent publication of the EMPA-REG Outcome and the LEADER studies demonstrating favorable CV outcomes with empagliflozin and liraglutide have led to a dec...
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2 diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current treatments are effective at reducing hyperglycaemia. GLP-1 exerts specific actions on the cardiovascular system in both healthy individuals and patients with cardiovascular pathology, and GLP-1 therapies have improved the cardiovascular profile of diabetic patients. GLP-1 exerts its action by binding to its receptor (GLP-1 receptor) at the cell surface. Mechanistically, it is not clear how GLP-1 therapies exert beneficial effects on the cardiovascular system. It i...
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
The impact of glucose-lowering medications on cardiovascular disease
Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease. Metabolic control is mandatory both for preventing long-term complications and for reducing the negative effects of the exposure of the other risk factors. In this article, we will describe the most commonly used glucose-lowering agents, the pathophysiological mechanisms underlying their cardiovascular protection, the available evidence-based data for this protection, and the contraindications and potential adverse effects. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Heart failure: an underestimated therapeutic target in diabetes
Heart failure (HF) is a frequent finding in patients with diabetes and is associated with an impaired prognosis with respect to the need for hospitalization as well as mortality. The following article presents an overview of the incidence and prognosis of HF in patients with type 2 diabetes and discusses the effects of various antidiabetic drugs on HF. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Pathophysiology of cardiovascular disease in diabetes mellitus
Diabetes mellitus elicits cellular, epigenetic, and post-translational changes that directly or indirectly affect the biology of the vasculature and other metabolic systems resulting in the apparition of cardiovascular disease. In this review, we provide a current perspective on the most recent discoveries in this field, with particular focus on hyperglycemia- induced pathology in the cardiovascular system. We also provide perspective on the clinical importance of molecular targeting of cardiovascular and diabetes mellitus therapies to treat hyperglycemia, inflammation, thrombosis, dyslipidemia, atherosclerosis, and hypert...
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Review articles Source Type: research
Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Editorials Source Type: research
Cardiovascular Endocrinology & Metabolism
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 19, 2018 Category: Cardiology Tags: Editorials Source Type: research
Oxford Diabetes Symposium 2017
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - December 1, 2017 Category: Cardiology Tags: Short report Source Type: research
